Varied Remimazolam Dosages for Pediatric Endoscopy
Status:
COMPLETED
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This prospective, randomized, comparative study aims to compare the efficacy and safety of three different doses of remimazolam (0.2 mg/kg, 0.3 mg/kg, and 0.4 mg/kg) combined with sufentanil and propofol for painless gastroscopy in pediatric patients. The study will assess sedation quality, propofol consumption, hemodynamic stability, and adverse event profiles to identify an optimal remimazolam dosing regimen.